Skip to main content
All lobbying filings

Professional Compounding Centers of America

Professional Compounding Centers of America filed a Q2 report for Professional Compounding Centers of America on July 20, 2026.

Lobbying for Professional Compounding Centers of America

As filed: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA.

All filings by Professional Compounding Centers of America · Everything Professional Compounding Centers of America has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$220,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Texas

Official filing document

 Lobbyists on this filing 1
  • CLAIRE CASEY New on this filing
    Previously held: Intern, Congressman Jim Himes - 9/21 - 12/21; Intern, House Appropriations Committee, Subcommittee on Homeland Security - 1/22 - 5/22; Intern, Senator Richard Blumenthal - 5/22 - 7/22; Intern, Congressman Jamie Raskin - 7/22 - 8/22

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Budget/Appropriations

Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill

Pharmacy

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act

Medicare/Medicaid

Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees

 Bills named in this filing 5

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem